YOU ARE HERE: LAT HomeCollectionsClinical Oncology

Clinical Oncology

May 21, 2000 | Reuters
A diabetes drug recently pulled from the market because of toxic liver effects may help in some cases of cancer and deserves further study, researchers said Saturday. They said they had found troglitazone, made by Warner-Lambert under the name Rezulin, had surprising effects on a few prostate cancer patients. "It's intriguing," Dr. Matthew Smith of the Dana-Farber Cancer Institute in Boston, who led the study, said in an interview.
November 18, 1987
Your editorial "New Focus in AIDS Fight" (Oct. 29) is both timely and appropriate. Dedication of federal and state funds for AIDS prevention and treatment is critical for successful control of this serious disease. But not all AIDS research and treatment are receiving government funding. Many of America's HIV-infected patients are cared for by private physicians without access to public-funded studies and programs. The Los Angeles Oncologic Institute, a private, nonprofit comprehensive cancer institute at St. Vincent Medical Center, includes AIDS research as a major component of its overall research program.
September 25, 2006 | From Times wire reports
Hormone therapy used to treat prostate cancer that has already spread might save patients from cancer but raise the risk of diabetes and heart disease. Writing in the Sept. 20 issue of the Journal of Clinical Oncology, researchers at Harvard Medical School said they examined the records of 73,000 men ages 66 and older who were diagnosed with local or regional prostate cancer.
May 20, 2002 | From Associated Press
An expert panel recommended Sunday that doctors stick with tamoxifen as the time-tested treatment for early-stage breast cancer, despite evidence that newer drugs may do a better job of preventing recurrence. The decision affects the care of about 700,000 women in the U.S. who take tamoxifen to prevent their breast cancer from coming back.
December 14, 2006 | From Bloomberg News
Genentech Inc.'s Avastin medicine prolonged the lives of patients with a form of recurrent or advanced lung cancer by two months, according to a study to be published today in the New England Journal of Medicine. The median survival time of patients who received Avastin in addition to chemotherapy was 12.3 months, compared with 10.3 for those getting just the chemicals, researchers said.
December 29, 2003 | Jane E. Allen
Obese men tend to develop more aggressive prostate cancers and have more recurrences after surgery than men who are of normal weight or simply overweight, two studies have found. Urologist Dr. Christopher Amling of the U.S. Naval Medical Center in San Diego led one study -- of 3,162 prostate cancer patients, 19% of whom were obese. Dr. Stephen J. Freedland, at the Johns Hopkins University School of Medicine, conducted the other study -- of 1,106 patients, 22% of whom were obese.
June 3, 2007 | From the Associated Press
The first scientific tests of some popular alternative medicine products hint that American ginseng might lessen cancer fatigue and that flaxseed might slow the growth of prostate tumors. But a big study indicated that shark cartilage was worthless against lung cancer, and doctors said people should not take it. The research was reported Saturday at an American Society of Clinical Oncology conference.
May 22, 2006 | From Times wire reports
Surgery appears to greatly increase a patient's chances of surviving with breast cancer, even if the cancer has spread by the time a woman is diagnosed. Although many women around the world are simply offered what is known as palliative care, to help them live a little longer and make them comfortable while they wait to die, surgery could help them live much longer, Swiss researchers found.
January 9, 2012 | By Shari Roan, Los Angeles Times / For the Booster Shots blog
Chemotherapy can destroy ovarian function in premenopausal women and much research has been dedicated to finding ways to preserve fertility in these women. Among breast cancer patients, for instance, about one in 200 are younger than age 40, and some of them may wish to become pregnant after successful cancer treatment. At least one of the strategies to preserve fertility in these women looks to be a failure, however. Researchers led by Dr. Pamela Munster at UC San Francisco conducted a study of premenopausal women undergoing chemotherapy.
May 27, 1991 | From Times Staff and Wire Reports
Most doctors don't give enough painkillers to ease the suffering of cancer victims, and nearly two-thirds admit they do a poor job of even learning if their patients hurt, according to a study released last week. The major reason doctors don't treat pain aggressively enough is their fear that they will not be able to deal with side effects of the medicines, the study found.
Los Angeles Times Articles